Notably, the FDA approved the use of pembrolizumab across solid tumors for patients with MSI-H metastatic disease and no satisfactory alternative treatments, meaning that patients with MSI-H MBC could qualify for pembrolizumab regardless of their programmed death ligand 1 (PD-L1) status13. Here, CD274 is linked to metastatic neoplasm.